Leo J Hofland Selected Research

Somatostatin Receptors (Somatostatin Receptor)

5/2022	Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor-Interacting Protein-mutated Pediatric Somatotropinoma.
11/2020	Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging.
1/2020	Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells.
8/2019	Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.
4/2019	Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
1/2019	Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
1/2019	Advances in the medical treatment of Cushing's syndrome.
3/2018	Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells.
1/2017	Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
1/2017	In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Leo J Hofland Research Topics

Disease

67	Neoplasms (Cancer) 08/2022 - 12/2002
24	Pituitary Neoplasms (Pituitary Adenoma) 05/2022 - 12/2003
22	Neuroendocrine Tumors (Neuroendocrine Tumor) 04/2022 - 02/2003
20	Adenoma (Adenomas) 06/2020 - 01/2003
14	Pancreatic Neoplasms (Pancreatic Cancer) 08/2022 - 05/2006
12	Pituitary ACTH Hypersecretion 06/2013 - 01/2004
11	Acromegaly 05/2022 - 12/2002
11	Cushing Syndrome 01/2021 - 08/2002
10	Adrenocortical Carcinoma 01/2020 - 11/2006
9	ACTH-Secreting Pituitary Adenoma 01/2021 - 01/2004
6	Neoplasm Metastasis (Metastasis) 04/2022 - 01/2005
6	Prolactinoma (Prolactinomas) 08/2019 - 01/2004
5	Carcinoid Tumor (Carcinoid) 01/2020 - 12/2002
5	Growth Hormone-Secreting Pituitary Adenoma 01/2017 - 02/2003
5	Hyperplasia 08/2014 - 01/2003
4	Fibrosis (Cirrhosis) 04/2022 - 01/2018
4	Insulin Resistance 10/2017 - 10/2009
4	Carcinoma (Carcinomatosis) 11/2010 - 09/2004
3	Thyroid Neoplasms (Thyroid Cancer) 03/2021 - 01/2017
3	Primitive Neuroectodermal Tumors (PNET) 03/2018 - 04/2015
3	Pheochromocytoma 01/2014 - 01/2004
3	Wounds and Injuries (Trauma) 01/2007 - 12/2004
2	medullary Thyroid cancer 01/2021 - 01/2017
2	Necrosis 08/2019 - 01/2017
2	Adrenal Cortex Neoplasms (Adrenocortical Cancer) 01/2019 - 01/2014
2	Gastro-enteropancreatic neuroendocrine tumor 01/2016 - 01/2016
2	Adenocarcinoma 01/2015 - 08/2007
2	Islet Cell Adenoma (Islet Cell Tumors) 02/2003 - 12/2002
1	Gigantism 05/2022
1	Disease Progression 05/2022

Drug/Important Bio-Agent (IBA)

36	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 05/2022 - 12/2002
32	Somatostatin Receptors (Somatostatin Receptor)IBA 05/2022 - 12/2002
20	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2021 - 08/2002
17	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2019 - 01/2003
14	Octreotide (Sandostatin)FDA LinkGeneric 11/2019 - 12/2002
13	Messenger RNA (mRNA)IBA 01/2022 - 01/2003
11	pasireotideIBA 06/2020 - 01/2004
10	Hormones (Hormone)IBA 01/2021 - 12/2002
9	Interferon Type IIBA 03/2021 - 11/2006
9	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 04/2008
9	Dopamine Agonists (Dopamine Agonist)IBA 08/2019 - 05/2004
8	Cabergoline FDA LinkGeneric 01/2019 - 05/2004
8	Dopamine Receptors (Dopamine Receptor)IBA 02/2013 - 05/2004
7	Proteins (Proteins, Gene)FDA Link 04/2022 - 01/2013
7	Radioisotopes (Radionuclides)IBA 09/2021 - 12/2002
6	Peptide Receptors (Peptide Receptor)IBA 09/2021 - 01/2005
6	Insulin (Novolin)FDA Link 01/2021 - 10/2009
6	Insulin-Like PeptidesIBA 01/2021 - 01/2015
6	Growth Hormone (Somatotropin)IBA 01/2017 - 04/2004
6	InterferonsIBA 01/2015 - 11/2006
5	Insulin-Like Growth Factor I (IGF-1)IBA 06/2020 - 02/2010
4	Gemcitabine FDA Link 08/2022 - 05/2013
4	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 10/2009
4	Ketoconazole (Nizoral)FDA LinkGeneric 01/2021 - 05/2010
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021 - 01/2018
4	Pharmaceutical PreparationsIBA 11/2019 - 01/2017
4	GhrelinIBA 01/2017 - 06/2006
4	ProlactinIBA 02/2015 - 04/2004
3	lanreotide (Somatuline)FDA Link 01/2021 - 01/2004
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2012
3	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2017
3	Temozolomide (Temodar)FDA LinkGeneric 10/2020 - 11/2010
3	Mitotane (Lysodren)FDA Link 01/2020 - 06/2013
3	LigandsIBA 08/2019 - 04/2005
3	MTOR InhibitorsIBA 01/2019 - 06/2012
3	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2016 - 12/2003
3	Reactive Oxygen Species (Oxygen Radicals)IBA 06/2007 - 01/2007
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2006 - 12/2004
3	CytokinesIBA 09/2006 - 12/2004
2	somatostatin receptor 5IBA 05/2022 - 04/2005
2	Serotonin (5 Hydroxytryptamine)IBA 04/2022 - 01/2020
2	Histone Deacetylase InhibitorsIBA 02/2022 - 09/2021
2	SteroidsIBA 01/2022 - 01/2021
2	pegvisomant FDA LinkGeneric 06/2020 - 01/2017
2	177Lu-octreotateIBA 04/2019 - 01/2016
2	somatostatin receptor 2IBA 04/2019 - 01/2009
2	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2003
2	Circulating Tumor DNAIBA 01/2019 - 10/2017
2	Peptides (Polypeptides)IBA 01/2019 - 01/2018
2	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 12/2017 - 03/2012
2	Everolimus FDA Link 01/2017 - 03/2016
2	Ghrelin ReceptorsIBA 01/2017 - 06/2006
2	Sirolimus (Rapamycin)FDA Link 06/2016 - 08/2014
2	ArrestinsIBA 05/2016 - 12/2013
2	ArrestinIBA 05/2016 - 12/2013
2	Protein Isoforms (Isoforms)IBA 01/2016 - 09/2004
2	Insulin ReceptorIBA 01/2016 - 01/2015
2	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 01/2015 - 03/2014
2	Angiotensin IIIBA 09/2013 - 09/2004
2	EnzymesIBA 09/2013 - 01/2007
2	CatecholaminesIBA 09/2013 - 08/2002
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 05/2013 - 01/2012
2	Monoclonal AntibodiesIBA 01/2013 - 12/2004
2	AndrogensIBA 01/2013 - 09/2004
2	Interleukin-6 (Interleukin 6)IBA 09/2006 - 05/2006
1	aryl hydrocarbon receptor-interacting proteinIBA 05/2022
1	Tryptophan (L-Tryptophan)FDA Link 04/2022

Therapy/Procedure

30	Therapeutics 09/2021 - 02/2003
7	Drug Therapy (Chemotherapy) 01/2021 - 02/2003
7	Radiotherapy 08/2019 - 12/2002